---
figid: PMC6696099__ijms-20-03624-g001
figtitle: Proposed targeting approaches involving ACSL isoenzymes in cancer
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Drosophila melanogaster
- Ananas comosus
- Lactobacillus gasseri
organisms_ner:
- Mus musculus
- Homo sapiens
- Rattus norvegicus
- Drosophila melanogaster
- Caenorhabditis elegans
- Arabidopsis thaliana
pmcid: PMC6696099
filename: ijms-20-03624-g001.jpg
figlink: /pmc/articles/PMC6696099/figure/ijms-20-03624-f001/
number: F1
caption: Proposed targeting approaches involving ACSL isoenzymes in cancer. (A) ACSL1
  and glycolytic pathway co-targeting in colon cancer (red), and ACSL1 single targeting
  breast cancer (blue). (B) ACSL3, CPT1 and the mammalian target of rapamycin complex
  1 (mTORC1) co-targeting in lung cancer (red) and the combination of ACSL3 inhibition
  with ER stress inducers in lung and prostate cancer. (C) Combined ACSL4 and SCD1
  inhibition in colon cancer (red) and ACSL4 indirect targeting via the p38 MAPK pathway
  inhibition in liver cancer (blue). (D) ACSL5 and Topoisomerase II (Topo II) co-targeting
  with a potential therapeutic benefit in glioma.
papertitle: Targeting Long Chain Acyl-CoA Synthetases for Cancer Therapy.
reftext: Matteo Rossi Sebastiano, et al. Int J Mol Sci. 2019 Aug;20(15):3624.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9036899
figid_alias: PMC6696099__F1
figtype: Figure
redirect_from: /figures/PMC6696099__F1
ndex: e2a44440-de99-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6696099__ijms-20-03624-g001.html
  '@type': Dataset
  description: Proposed targeting approaches involving ACSL isoenzymes in cancer.
    (A) ACSL1 and glycolytic pathway co-targeting in colon cancer (red), and ACSL1
    single targeting breast cancer (blue). (B) ACSL3, CPT1 and the mammalian target
    of rapamycin complex 1 (mTORC1) co-targeting in lung cancer (red) and the combination
    of ACSL3 inhibition with ER stress inducers in lung and prostate cancer. (C) Combined
    ACSL4 and SCD1 inhibition in colon cancer (red) and ACSL4 indirect targeting via
    the p38 MAPK pathway inhibition in liver cancer (blue). (D) ACSL5 and Topoisomerase
    II (Topo II) co-targeting with a potential therapeutic benefit in glioma.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Acsl1
  - Acsl3
  - Mir19b-2
  - Acy1
  - Hps3
  - .na.character
  - Srebf1
  - Cpt1a
  - Cpt1b
  - Acsl4
  - Apk
  - Scd1
  - ACSL1
  - ACSL3
  - MIR19B1
  - ACY1
  - ATP8A2
  - SREBF1
  - CPT1A
  - CPT2
  - CHPT1
  - ACSL4
  - ABCB6
  - SCD
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - Scd
  - CG3961
  - Acsl
  - Coa
  - Low
  - ATPsynbeta
  - Atpalpha
  - SREBP
  - whd
  - SRPK
  - hh
  - Nplp1
  - MKP-4
  - p38b
  - rl
  - Top2
  - acy-1
  - cpt-1
  - scd-1
  - cPT1
  - APK
  - SCD1
  - Fatty acids
  - Glucose
  - Triacsin C
  - Acyl
  - Acyl CoAs
  - ATP
  - Bromo-CAMP
  - Etoposide
  - Thiazolidinediones
  - acidosis
---
